<?xml version="1.0" encoding="UTF-8"?>
<p>A recent cohort study evaluated the effect of anakinra on SARS-CoV-2-related hyperinflammatory state, in COVID-19 patients. The authors stated that anakinra significantly reduced both the need for invasive mechanical ventilation in the intensive care unit (ICU) and mortality among patients with severe COVID-19, without serious side-effects. The study also suggests that, so far, no other specific treatment has been shown to reduce the need for invasive mechanical ventilation and intensive care in patients admitted for COVID-19-associated pneumonia requiring oxygen therapy [
 <xref rid="B144-jcm-09-02084" ref-type="bibr">144</xref>]. Up to this date, there are 10 ongoing clinical trials involving the use of anakinra as a COVID-19 potential therapy [
 <xref rid="B145-jcm-09-02084" ref-type="bibr">145</xref>].
</p>
